- Stocks
- Pharma & Healthcare
- Global Longlife
Global Longlife share price
NSE: GLHRLPharma & HealthcareMedical Care Facilities
Global Longlife at a glance
With a market capitalisation of ₹10 Cr, it ranks 3891st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
Its return on equity was 0.7% in FY25. Promoters held 22.88% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹10 CrRank 3891 on NSE
- Price to book
- 0.74×FY25
- ROE
- 0.7%FY25
- ROCE
- 1.4%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 34.4%FY25
- Book value / share
- ₹25.51FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Global Longlife financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹33 Cr | ₹24 Cr | ₹14 Cr | ₹1 Cr |
| Operating profit | ₹6 Cr | ₹3 Cr | −₹2 Cr | ₹0 Cr |
| Net profit | ₹4 Cr | ₹2 Cr | −₹2 Cr | ₹0 Cr |
| EPS (₹) | ₹5.11 | ₹1.79 | −₹2.08 | ₹0.19 |
| Cash from operations | ₹9 Cr | −₹40 Cr | −₹5 Cr | ₹12 Cr |
| Total debt | ₹3 Cr | ₹4 Cr | ₹3 Cr | ₹0 Cr |
| Shareholders' equity | ₹17 Cr | ₹64 Cr | ₹26 Cr | ₹27 Cr |
Global Longlife shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 54.29% | 54.90% | 55.10% | 35.44% | 22.88% | 22.88% |
| Non-institutions | 45.71% | 45.10% | 44.90% | 64.56% | 77.12% | 77.12% |
Global Longlife vs peers
The listed Pharma & Healthcare companies nearest to Global Longlife by market capitalisation.
Ask anything about Global Longlife
Pivot answers on the live chart with evidence you can check, and tests strategies against GLHRL's own history. Try: “Why has GLHRL moved over the last three months?” · “Backtest a 50-day moving-average crossover on GLHRL over five years” · “Compare GLHRL with ORTINGLOBE on margins and valuation”
Frequently asked questions about Global Longlife
What is the market cap of Global Longlife?
Global Longlife's market capitalisation is ₹10 Cr (₹10 Cr) at the 22 Oct 2026 close, ranking 3891st among the NSE companies Pivot tracks.
What is the ROE and ROCE of Global Longlife?
Return on equity was 0.7% in FY25 and return on capital employed was 1.4% in FY25 (standalone figures).
Is Global Longlife a debt-free company?
Global Longlife is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What is the shareholding pattern of Global Longlife?
As of 30 Jun 2026: promoters 22.88%, non-institutions 77.12%.
Who are Global Longlife's competitors?
The listed Pharma & Healthcare companies closest to Global Longlife by market cap are ORTIN GLOBAL, Beryl Drugs, Looks Health, Broach Lifecare, Clinitech Labor and Genomic Valley.
Is Global Longlife a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Global Longlife's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GLHRL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text